v3.23.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 45,898 $ 92,942
Short-term investments 107,744 149,877
Restricted cash 146 146
Accounts receivable 507 40,221
Inventories 7,861 1,586
Other current assets 10,164 10,308
Total current assets 172,320 295,080
Property and equipment, net 5,349 6,300
Operating lease assets 62,195 68,022
Other assets 6,575 7,018
Total assets 246,439 376,420
Current liabilities:    
Accounts payable 4,138 6,871
Accrued compensation 12,556 17,659
Accrued research and development expenses 20,737 24,992
Deferred revenue 11,949 8,000
Other current liabilities 25,172 21,394
Total current liabilities 74,552 78,916
Deferred revenue - long-term 75,565 77,000
Operating lease liabilities - long-term 51,754 58,064
Liability related to the sale of future revenues - long-term 32,091 30,236
Other long-term liabilities 5,023 5,564
Total liabilities 238,985 249,780
Commitments and contingencies (Note 8)
Stockholders’ equity:    
Common stock-$0.0001 par value, 500,000 shares authorized as of June 30, 2023 and December 31, 2022; 101,102 and 95,927 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively 10 10
Additional paid-in capital 1,847,280 1,821,721
Accumulated other comprehensive (loss) income (933) (2,067)
Accumulated deficit (1,838,903) (1,693,024)
Total stockholders’ equity 7,454 126,640
Total liabilities and stockholders’ equity $ 246,439 $ 376,420

Source

10-Q
HTML PDF
XBRL
ZIP